Are You a Candidate for Peptide Therapy? Labs, Foundations First, and Safety Questions to Ask

By Dr. Leandro Pucci, DCN, CNS, CKNS, LDN

 

You are a reasonable candidate for peptide therapy when five things are true: a specific, measured problem; a foundation of nutrition, training, and sleep that has been in place long enough to judge; a peptide whose mechanism matches the problem and has human evidence behind it; no contraindications; and a legal, monitored source with a plan for stopping. Most people who ask me about peptides meet two or three of these. The missing ones are usually where the real work is.

 

This article is the practical companion to my guides on peptides for metabolic health and the evidence behind specific peptides. It walks through how I decide, with patients and their prescribers, whether a peptide belongs in a plan.

 

 

Five Questions to Answer Before Any Peptide

 

1. What exactly are we treating, and how is it measured?

"Optimization" is not a target. Visceral fat on a body composition scan, a HOMA-IR of 4.2, a fasting insulin that has not moved, or a BMI that meets medical criteria for treatment are targets. Without a baseline number, there is no way to tell whether a peptide is working or simply adding cost and risk.

 

2. Has the foundation had a fair trial?

I ask for 8 to 12 weeks of consistent protein intake, carbohydrate matched to insulin sensitivity, resistance training, and protected sleep before deciding a peptide is needed. Many patients reach their goals in that window. Those who do not now have data showing what the foundation could and could not change, which makes the peptide decision sharper. A 2025 joint advisory on GLP-1 therapy from four professional societies makes the same point: baseline assessment of diet, strength, body composition, sleep, and stress belongs before and alongside treatment (1).

 

3. Does the mechanism match, with human evidence?

A GLP-1 medication addresses appetite regulation and glucose control and has large randomized trials behind it (2). Tesamorelin addresses visceral fat, with trial evidence in a specific population (3). Many popular peptides have animal data only. Matching the mechanism to the measured problem, and being honest about the evidence level, prevents a lot of disappointment.

 

4. Is it safe for you specifically?

Every peptide class has people it is not suited for. This is a conversation with the prescribing clinician, informed by your history and labs (see the table below).

 

5. Is it legal, pharmacy-made, monitored, and does it have an exit plan?

The trial data on stopping GLP-1 medications are clear: in STEP 4, participants switched to placebo regained 6.9% of body weight within 48 weeks (4), and in the STEP 1 extension most participants regained about two-thirds of their lost weight in a year (5). Deciding in advance how success will be judged, and what a taper or maintenance phase will look like, is part of starting well.

 

Who Tends to Be a Good Candidate, and Who Is Not

 

GLP-1 medications and dual agonists may be considered for individuals with a BMI of 30 or higher, or 27 or higher with a weight-related health condition, after completing a structured lifestyle foundation phase. These medications are FDA-approved for specific weight-management indications. Important precautions to discuss with a prescriber include a personal or family history of medullary thyroid cancer or MEN2, a history of pancreatitis, pregnancy or plans to become pregnant, and current or past eating disorders.

 

For individuals with type 2 diabetes or MASH with fibrosis, GLP-1 medications may also be considered for their FDA-approved indications. The same precautions apply, and treatment should be coordinated with the treating physician.

 

Tesamorelin is FDA-approved for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Important considerations include diabetes control, active cancer, and pregnancy.

 

For individuals pursuing visceral fat reduction or body composition goals without HIV, growth hormone-axis peptides are sometimes discussed, although these uses may be off-label or not FDA-approved. These compounds require particular caution because insulin resistance can worsen. One related compound was associated with increased fasting glucose and reduced insulin sensitivity in a one-year trial (6). Active or past cancer also warrants special caution with therapies that raise IGF-1.

 

Finally, BPC-157 and TB-500 are sometimes discussed for gut, joint, or recovery-related complaints. However, these compounds are not FDA-approved, and their human safety profiles remain unknown. Their legal status is also unresolved. Animal evidence should not be interpreted as proof of safety or effectiveness in humans.

 

The is a framework for a conversation, not a prescription guide. Decisions are individual and belong with a licensed prescriber.

 

 

Baseline Labs and Monitoring

 

The specific panel depends on the peptide and your history, but these are the markers I want before starting and at intervals afterward:

 

Fasting insulin, glucose, HOMA-IR, and A1c help define the underlying metabolic picture and identify insulin resistance or blood sugar imbalances. These markers are especially important to evaluate before considering any growth hormone-axis peptide therapy.

 

A lipid panel and ApoB establish a cardiovascular health baseline and help assess cholesterol-related risk.

 

A complete metabolic panel (CMP) evaluates kidney and liver function, providing important information about overall metabolic health.

 

A complete blood count (CBC), ferritin, vitamin B12, and vitamin D help assess nutrient status and identify potential deficiencies, particularly before starting appetite-suppressing therapies.

 

Thyroid testing, including TSH, free T4, and free T3, helps evaluate thyroid function, which can influence weight, energy levels, and cholesterol.

 

IGF-1 (insulin-like growth factor 1) provides a baseline measurement and helps monitor levels when growth hormone-axis peptides are being considered.

 

Finally, body composition testing, using a DXA scan or validated scale, helps track changes in fat mass and lean muscle mass rather than relying on body weight alone.

 

Retesting at about three months, and then at intervals set with the prescriber, shows whether the peptide is doing what it was chosen to do.

 

Red Flags in Peptide Marketing

 

The peptide market moved faster than regulation, and some sellers exploit the gap. Be cautious when you see:

  • "Research use only" or "not for human consumption" labels. These products are sold outside pharmacy oversight, and their purity, dose, and sterility are unverified.
  • No prescription or clinical evaluation required. Any peptide worth taking is worth a medical history and labs.
  • Outcome promises without trial data. Fat loss, healing, longevity, or cognitive claims for peptides that have only been tested in animals.
  • Proprietary blends and stacks. Combinations of multiple peptides, or GLP-1s blended with vitamins, have not been tested in trials. The FDA has warned that compounded GLP-1 products are not approved and has moved to restrict them (8).
  • "FDA-approved" or "FDA-registered" claims for compounded or research peptides. None of the popular non-GLP-1 wellness peptides is an approved drug. A July 2026 FDA advisory vote favoring compounding access for several of them was advisory only (7), and formal policy was still pending in October 2026 (9).
  •  

How Peptide Consultation Works in My Practice

 

As a clinical nutritionist, I don't prescribe. My role is to assess whether a peptide fits your metabolic picture, build the foundation that makes it more effective and the results more durable, and coordinate with a licensed prescriber who evaluates you and manages the medication. In practice, that looks like:

  1. Assessment: health history, symptoms, current labs, body composition, and goals.
  2. Foundation phase: 8 to 12 weeks of targeted nutrition, training, and sleep changes, with retesting.
  3. Peptide decision: if a measurable gap remains, a referral or coordination with your prescriber, with the evidence and expectations laid out clearly.
  4. Monitoring: nutrition support during therapy (protein, micronutrients, muscle preservation), labs at set intervals, and body composition tracking.
  5. Exit planning: a defined plan for maintenance or taper, built before it is needed.

Frequently Asked Questions

 

Who should not take peptides?

It depends on the peptide. For GLP-1 medications, a personal or family history of medullary thyroid cancer or MEN2, a history of pancreatitis, pregnancy, and active eating disorders are common reasons for caution or exclusion. For growth hormone-axis peptides, poorly controlled diabetes and a history of cancer require careful review.

 

What labs should I get before starting a peptide?

At minimum: fasting insulin and glucose, A1c, a lipid panel with ApoB, a complete metabolic panel (CMP), CBC, and thyroid function. IGF-1 is added for growth hormone-axis peptides, and nutrient markers before appetite-suppressing therapy.

 

Do I need a prescription for peptides?

Approved peptide medications require a prescription. Compounded peptides also require a prescription from a licensed clinician and must come from a licensed pharmacy. Products sold without a prescription are not regulated for human use.

 

How long should I try diet and exercise before considering a peptide?

I recommend 8 to 12 weeks of a consistent, well-designed foundation phase with baseline and follow-up labs. That window is long enough to see meaningful changes in insulin, triglycerides, and body composition.

 

What happens when I stop a peptide?

For GLP-1 medications, trials show most of the lost weight returns within a year after stopping unless the habits and muscle built during treatment are maintained. Planning the exit before starting improves the odds of keeping results.


Wondering whether a peptide fits your situation? Peptide consultation, access coordination, and support are part of my Metabolic Optimization program, built on your labs and a foundation that lasts. Book a discovery call or see how I work with patients.

 

This article is for educational purposes and is not medical advice. Peptide therapies require evaluation and prescription by a licensed clinician.


References

  1. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367. doi:10.1016/j.ajcnut.2025.04.023
  2. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
  3. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. doi:10.1056/NEJMoa072375
  4. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224
  5. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725
  6. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-611. doi:10.7326/0003-4819-149-9-200811040-00003
  7. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov
  8. Compounded GLP-1s: why doctors worry and the FDA is cracking down. Stanford Medicine. July 2026. med.stanford.edu
  9. US FDA takes step to change peptide compounding policy. Reuters. October 15, 2026. reuters.com

Regulatory status verified October 25, 2026.



You might also like...

Nutrigenomics Testing in Practice What Your Genes Can and Can't Tell You About Nutrition
By Dr. Leandro Pucci, DCN, CNS, CKNS, LDN A nutrigenomic test can tell you how your body is likely to handle specific nutrients: how fast you ...
Read More →
How to Boost Wellness with Simple Self-Improvement Steps You Can Start Now
For busy parents juggling work and wellness, the biggest frustration is often feeling stuck between good intentions and inconsistent follow-through...
Read More →
Smart Batch Cooking for Weeks That Never Slow Down
Smart Batch Cooking for Weeks That Never Slow DownMeal prepping is a practical response to crowded calendars and decision fatigue, not a rigid life...
Read More →
Precision Metabolic Optimization: Harnessing Nutrigenomics and Functional Lab Panels for Personalized Nutrition
The "one-size-fits-all" approach to metabolic health has failed the American population. Despite decades of adherence to generalized dietary guidel...
Read More →